Munich – T-knife GmbH, a biotech start-up operating in the field of T-cell therapy against cancer, has completed a EUR 66 million Series A financing round. The round was led by highly regarded US investors Versant Ventures and RA Capital Management. The existing investors, Andera Partners and Boehringer Ingelheim Venture Fund (BIVF), also contributed significant amounts. T-knife’s objective is to become a transatlantic company by establishing a US presence and expanding its management team accordingly. The transaction is currently awaiting approval from the relevant authorities.
A CMS team headed by lead partner Stefan-Ulrich Müller advised T-knife on all legal aspects of the Series A financing. CMS’s Munich-based venture capital and life sciences team has been advising the biotech start-up on all legal matters since its seed financing round.
T-knife GmbH is a biotech start-up headquartered in Berlin that develops innovative targeted immune therapies for the treatment of cancer. It uses the body’s own immune cells (T-cells) and modifies them genetically using recombinant molecules (T-cell receptors). The company was founded in 2018 as a spin-off from the Max Delbrück Center for Molecular Medicine with support from Charité University Hospital in Berlin.
Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Partner
Sebastian Hummel, Research Associate, all Corporate/Venture Capital
Stefan Lüft, Partner
Annika Lindemann, Associate, both Intellectual Property
Stefan Lehr, Partner, Competition & EU
Jörg Schrade, Partner
Dr Isabella Denninger, Senior Associate, both Tax
Dr Christoph Ceelen, Counsel, Labor, Employment & Pensions